跳至主要内容
临床试验/CTRI/2018/10/016051
CTRI/2018/10/016051已完成4 期

A prospective, single-arm, open-label, multi-centric to determine the safety and effectiveness of Anafortan â??N. Fixed-dose combination of Camylofin Dihydrochloride 50mg and Nimesulide 100mg in patients with acute colicky abdominal pain in India - AHPLIN1701

Abbott Healthcare Pvt Ltd0 个研究点目标入组 295 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
295

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male or female patients aged >=18 years to 65 years
  • Patients presenting with acute colicky abdominal pain and having history of at least 1 episode within a 24 hour period prior to screening with no other concomitant illness.
  • Patients willing and able to provide written informed consent

排除标准

  • 1.Patients with history of taking Anafortan-N® or any other prescription analgesics and antispasmodics medication (within the previous 1 weeks before study enrollment)
  • 2.Pregnant and lactating women
  • 3.History of hypersensitivity/allergy to study drug
  • 4.Cognitive impairment, alcohol abuse, or psychiatric illness that would affect the ability of the patient to complete patient diary and other assessments
  • 5.Any other illness or conditions that does not justify patientâ??s participation in the study as judged by the Investigator
  • 6.Patients not willing to comply with the study procedures

研究者

相似试验